Biosimilars in Ovarian Cancer

Ovarian cancer is a deadly malignancy and remains to be a formidable challenge in respect to oncology, that is characterized by its insidious onset, aggressive nature, and limited treatment options. Despite the research in conventional and targeted delivery, the management of ovarian cancer requires a novel therapeutic strategy to improve the quality of life. Biologics have been increasingly used for the management of ovarian cancer, but their high cost and stability add a significant burden among the pharmaceutical companies and patients. Therefore, a promising alternative in reference to biologics is used providing improved efficacy and safety and reduced cost. Leveraging the principles of biotechnology and molecular biology, biosimilars have paved the way for enhanced accessibility to biologic therapies, addressing unmet medical needs across various disease states, including cancer. In response to these challenges, researchers and clinicians are increasingly focusing on advancing drug delivery systems to optimize the efficacy, safety, and accessibility of biosimilar therapies. From nanotechnology-based formulations to targeted delivery strategies and innovative biomaterials, recent developments offer promising avenues for overcoming delivery-related obstacles and enhancing the clinical utility of biosimilars in ovarian cancer treatment. This chapter aims to provide a comprehensive overview of the utilization of biosimilars in ovarian cancer management, elucidating the challenges faced in their delivery and exploring recent advancements in drug delivery systems. By integrating insights from clinical research, regulatory perspectives, and technological innovations, this discussion seeks to inform and empower stakeholders in navigating the dynamic landscape of biosimilar-based therapies for ovarian cancer.